Actively Recruiting
Familial Systemic Scleroderma
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
CONDITIONS
Official Title
Familial Systemic Scleroderma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult subjects (≥ 18 years of age)
- Diagnosed with systemic scleroderma by a clinician, including limited, diffuse, and sine forms, or overlap syndromes with myositis
- Meets at least the VEDOSS criteria: Raynaud's phenomenon plus one other criterion such as sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), or capillaroscopic abnormalities
- Has at least one first-degree relative with systemic scleroderma meeting the same criteria
You will not qualify if you...
- Individuals who have expressed opposition to participating in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Aurélien GUFFROY, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here